Clinical Trial

A Study to Test the Long-term Treatment of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa

Study acronym: BE HEARD EXT
Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
The purpose of the study is to evaluate the safety of long-term therapy of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
Protocol Amendment History 100 amendments
This ClinicalTrials.gov record has been amended 100 times since 2021-05-20; most recent amendment 2026-06-18.
Status change: Enrolling by Invitation → Active, Not Recruiting 2023-01-30
Status change: Not Yet Recruiting → Enrolling by Invitation 2021-06-08
Trial Details
NCT Number NCT04901195
Lead Sponsor UCB Biopharma SRL
Conditions Hidradenitis Suppurativa
Enrollment 658 participants
Start Date 2021-05-27
Primary Completion 2026-07-28 (estimated)
Study Completion 2026-07-28 (estimated)
Updated on ClinicalTrials.gov 2026-07-31